Approximately 20% to 30% of all people who suffer from psoriasis also develop painful inflammation in their joints over time.

Topline data were announced from a phase 3b trial evaluating the concomitant use of ixekizumab and tirzepatide in active PsA and obesity.

Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.

Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...

SKYWAY (NCT07148414) is a Phase 2 basket trial of SPY072 (anti-TL1A) in patients with moderate to severely active RA, PsA, or axSpA. Enrollment is on track, and all indications are expected to readout ...

Two patients present with rash eruptions on different parts of the body. Can you correctly identify each case?

People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.

In a phase IIIb trial of adults with active psoriatic arthritis (PsA) and obesity or overweight, adding the GLP-1 drug ...

Eli Lilly said combining Taltz and Zepbound improved arthritis symptoms and drove meaningful weight loss, outperforming Taltz ...

Data from the first in human study on O3R-5671’s potent TNFα inhibition to be presentedDosing of the final cohort in the first in human study has ...